ProfileGDS5678 / 1426524_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 88% 88% 89% 87% 88% 88% 83% 86% 87% 88% 89% 88% 88% 89% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.7486288
GSM967853U87-EV human glioblastoma xenograft - Control 26.8165988
GSM967854U87-EV human glioblastoma xenograft - Control 37.0904789
GSM967855U87-EV human glioblastoma xenograft - Control 46.9003187
GSM967856U87-EV human glioblastoma xenograft - Control 56.9071588
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.5504188
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.9073283
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.5580286
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.6738487
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.9120788
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.9101789
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.9746588
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.81288
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.9399689